Ivarmacitinib软膏治疗成人轻中度特应性皮炎:随机双盲安慰剂对照II/III期临床试验的III期结果
该研究为在中国27家中心开展的多中心随机双盲载体对照无缝适应性II/III期试验的III期部分,纳入367例18-75岁轻中度特应性皮炎成人,按1:1:1随机接受ivarmacitinib软膏0.5%、1%或载体每日两次治疗8周。主要终点为第8周IGA应答和EASI 75,ivarmacitinib两组均显著优于载体,瘙痒缓解在48小时内出现并维持至52周,安全性良好。
要点
- ivarmacitinib软膏0.5%和1%每日两次可显著改善轻中度AD的IGA应答和EASI 75。
- 瘙痒缓解在48小时内出现,并维持至第52周。
- 安全性良好,未见皮肤萎缩、毛细血管扩张或应用部位刺激。
核心结论
- 每日两次ivarmacitinib软膏(0.5%或1%)对成人轻中度特应性皮炎产生快速、持久且耐受良好的体征、症状和瘙痒改善,支持其作为安全、节省激素的外用治疗选择。
研究设计与样本
- 研究为在中国27家中心开展的多中心随机双盲载体对照无缝适应性II/III期试验的III期部分。
- 纳入367例18-75岁符合Hanifin-Rajka标准的轻中度特应性皮炎成人,按1:1:1随机接受ivarmacitinib软膏0.5%、1%或载体每日两次治疗8周。
- 初始接受载体的患者在盲法延长期重新随机至活性治疗至第52周。
主要发现
- 第8周IGA应答率:ivarmacitinib 0.5%组21.3% vs 载体组10.6%(P=0.02);ivarmacitinib 1%组26.2% vs 载体组10.6%(P=0.001)。
- 第8周EASI 75应答率:ivarmacitinib 0.5%组42.6% vs 载体组17.9%;ivarmacitinib 1%组45.1% vs 载体组17.9%(均P<0.001)。
- 瘙痒缓解在48小时内出现并维持至第52周,SCORAD、受累体表面积和DLQI持续改善。
- 载体对照期间,治疗中出现的不良事件发生率:ivarmacitinib 0.5%组42.6%(52/122)、ivarmacitinib 1%组56.6%(69/122)、载体组52.0%(64/123),大多为轻度,感染相关事件不常见。
- ivarmacitinib 1%组或载体组无治疗相关不良事件发生率≥2%;ivarmacitinib 0.5%组仅毛囊炎(5/122;4.1%)和血尿酸升高(4/122;3.3%)报告发生率≥2%。
关键数值与推荐
- 共同主要终点为第8周IGA应答(评分0/1且改善≥2级)和EASI 75。
- 随机化比例为1:1:1,治疗8周,延长期至第52周。
- 入组年龄18-75岁,Hanifin-Rajka标准定义轻中度AD。
临床怎么用
- ivarmacitinib软膏0.5%或1%每日两次可作为成人轻中度AD的潜在外用治疗选择,尤其适合需要长期管理且希望避免激素相关风险的患者。
- 治疗可快速缓解瘙痒(48小时内),并持续改善皮损和生活质量至52周,支持长期使用。
- 安全性良好,未观察到皮肤萎缩或毛细血管扩张,但需注意毛囊炎和血尿酸升高(0.5%组发生率≥2%)。
局限性
- 研究仅在中国进行,结果可能受地域和人种限制。
- 延长期为盲法扩展,但载体对照仅8周,长期对照数据有限。
- 未报告与活性对照(如糖皮质激素或钙调神经磷酸酶抑制剂)的头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective topical therapies for mild-to-moderate atopic dermatitis (AD) should provide rapid itch relief, sustained anti-inflammatory efficacy and minimal local toxicity. Existing options, including corticosteroids and calcineurin inhibitors, are limited by long-term adverse effects, highlighting the need for safer, steroid-sparing alternatives. OBJECTIVES: To evaluate the efficacy and safety of ivarmacitinib ointment, a highly selective topical Janus kinase 1 inhibitor, applied twice daily in adults with mild-to-moderate AD. METHODS: This phase III evaluation was part of a multicentre randomized double-blind vehicle-controlled seamless adaptive phase II/III trial conducted at 27 sites in China. Adults aged 18-75 years with Hanifin-Rajka-defined mild-to-moderate AD were randomized (1 : 1 : 1) to ivarmacitinib ointment 0.5%, ivarmacitinib ointment 1% or vehicle for 8 weeks. Patients who initially received the vehicle were re-randomized to active treatment for a blinded extension through week 52. Co-primary endpoints were Investigator's Global Assessment (IGA) response (score 0/1 with ≥ 2-grade improvement) and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 8. RESULTS: At week 8, significantly more patients achieved an IGA response with ivarmacitinib than with vehicle [ivarmacitinib 0.5%: 21.3% vs. 10.6% (P = 0.02); ivarmacitinib 1%: 26.2% vs. 10.6% (P = 0.001)]. Likewise, EASI 75 responses were higher [ivarmacitinib 0.5%: 42.6% vs. 17.9%; ivarmacitinib 1%: 45.1% vs. 17.9% (both P < 0.001)]. Relief from pruritus was seen within 48 h and maintained through week 52, with sustained improvements in SCORing Atopic Dermatitis (SCORAD), affected body surface area and Dermatology Life Quality Index. During the vehicle-controlled period, treatment-emergent adverse events occurred in 42.6% (n = 52/122), 56.6% (n = 69/122) and 52.0% (n = 64/123) of patients in the ivarmacitinib 0.5%, ivarmacitinib 1% and vehicle groups, respectively; most were mild and infection-related events were infrequent. No treatment-related adverse event occurred in ≥ 2% of patients in the ivarmacitinib 1% or vehicle groups, while in the ivarmacitinib 0.5% group, only folliculitis (n = 5/122; 4.1%) and increased blood uric acid (n = 4/122; 3.3%) were reported in ≥ 2% of patients. No skin atrophy, telangiectasia or application-site irritation was observed. Long-term safety through week 52 remained consistent, with no new safety signals noted. CONCLUSIONS: Twice-daily ivarmacitinib ointment (0.5% or 1%) produced rapid, durable and well-tolerated improvements in the signs, symptoms and itch experienced by adults with mild-to-moderate AD, supporting its potential as a safe, steroid-sparing topical therapy. Atopic dermatitis is a chronic skin disease that causes itchy and inflamed areas of skin. It is also known as eczema. It is common, affects millions of people worldwide and can affect a person’s quality of life. Many current treatments can help, including steroid creams or drugs called calcineurin inhibitors. Long-term use of these treatments may lead to side effects such as skin thinning or irritation. We need safer and more targeted treatment options. Researchers at 27 hospitals in China tested a new cream called ‘ivarmacitinib’. This cream blocks a protein involved in inflammation and itching. In this study, 367 adults with mild-to-moderate disease divided into two groups. Some were given ivarmacitinib ointment. Others were given or a dummy cream (known as a ‘placebo’). Patients used their allocated cream twice daily for 8 weeks. After this, patients continued treatment for up to 1 year. We found that more patients using ivarmacitinib had clear or almost clear skin compared with patients using only the placebo cream. About 45% of patients using ivarmacitinib had a major improvement in their skin, compared with only 18% using the placebo cream. Relief from itching began within 2 days and lasted throughout the year of the study. Side effects, such as infections or colds, were mostly mild. We noted side effects in a similar number of patients in both groups. Importantly, there were no cases of skin thinning, visible blood vessels or irritation at the application site. These findings suggest that ivarmacitinib could offer adults with mild-to-moderate eczema a new treatment option. This treatment may provide fast and long-lasting relief from itching relief, without the risks associated with long-term steroid use.
引用
- Wang D, Wu J, Guo Q, et al. Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial. Br J Dermatol. 2026. PMID: 41317338. doi:10.1093/bjd/ljaf482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。